HOOKIPA Pharma Inc.: Business Overview, Financials & Competitive Analysis
HOOKIPA Pharma Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). HOOKIPA's transition from clinical-stage development company to liquidation mode reflects fundamental challenges in biotech funding and clinical execution. HOOKIPA faces severe strategic challenges with voluntary delisting announcement, asset sales, and company dissolution plans. The company has divested key oncology programs and partnered away its infectious disease pipeline to Gilead.
What is HOOKIPA Pharma Inc.'s industry? HOOKIPA Pharma Inc. (hookipapharma.com) operates in Biopharmaceutical / Immunotherapeutics. AskCyborg classifies HOOKIPA Pharma Inc. under Biopharmaceutical / Immunotherapeutics in its company registry.
HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics based on its proprietary arenavirus platform. The company's pipeline targets cancer and infectious diseases, w...
Cyborg Score thesis
HOOKIPA's transition from clinical-stage development company to liquidation mode reflects fundamental challenges in biotech...
Read the full analyst-debate transcript →Get the Latest HOOKIPA Pharma Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHOOKIPA Pharma Inc. Overview
Pro stress-test →HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics based on its proprietary arenavirus platform. The company's pipeline targets cancer and infectious diseases, with programs in development for HPV+ head and neck cancers, hepatitis B, and HIV in collaboration with Gilead Sciences. The company is undergoing significant restructuring, including asset sales and voluntary delisting from NASDAQ.
Strategic Profile
Pro stress-test →HOOKIPA leverages a differentiated arenavirus platform that reprograms the immune system to target multiple therapeutic areas. The company has established strategic partnerships with Gilead Sciences for HB-400 (hepatitis B) and HB-500 (HIV) programs. However, recent asset dispositions signal a pivot toward liquidation, with immuno-oncology assets sold to NeoTrail Therapeutics in January 2026 and intention to delist from NASDAQ.
Competitive Landscape
Pro stress-test →HOOKIPA competes within the immuno-oncology and therapeutic vaccine space against companies like Immunomic Therapeutics, Celldex Therapeutics, and Altimmune. However, the competitive positioning is increasingly moot as the company executes its delisting and liquidation strategy. Prior to restructuring, the company differentiated through its arenavirus platform technology.
Industry Context
HOOKIPA Pharma Inc. operates in Biopharmaceutical / Immunotherapeutics.
Key facts
Founded: 2011 · Headquarters: New York, United States